Another HCC therapy in combination with sorafenib was generated by constructing charge-reversal nanocomplex, consisting of a negatively charged heparin core and positively charged ethanolamine (EA)-modified poly(glycidyl methacrylate) (PGEA) shell, termed Hep@PGEA, to deliver pCas9 and sgRNA targeting survivin [85]. The gene discussed is BIRC5; the disease is hepatocellular carcinoma.